Cytokinetics (NASDAQ: CYTK) completed a public offering of 11,338,028 shares of common stock at $71.00 per share, generating gross proceeds of approximately $805 million before underwriting fees and expenses.

The offering included the full exercise of underwriters' option to purchase an additional 1,478,873 shares. All shares were sold by the company.

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies served as joint book-running managers for the offering. Mizuho acted as lead co-manager, while Citizens Capital Markets, Needham & Company, B. Riley Securities and H.C. Wainwright & Co. served as co-managers.

The securities were offered under a shelf registration statement filed with the Securities and Exchange Commission on February 27, 2025. A final prospectus supplement and accompanying prospectus have been filed with the SEC.

Cytokinetics is a cardiovascular biopharmaceutical company with an approved cardiac myosin inhibitor called MYQORZO (aficamten) for treating adults with symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe and China. The company is also developing omecamtiv mecarbil for heart failure patients with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction.